364 Beneficial Actions of SGLT2 Inhibition and H2S Therapy in Heart Failure with Preserved Ejection Fraction

OBJECTIVES/GOALS: SGLT2i therapy is currently a cornerstone in heart failure with preserved ejection fraction (HFpEF) therapy. Similarly, H2S has been shown to be beneficial in preclinical models of heart failure. With this in mind, we sought to investigate the effects of the SGLT2i and H2S donor th...

Descripción completa

Detalles Bibliográficos
Autores principales: Doiron, Jake, Li, Zhen, Xia, Huijing, Lapenna, Kyle B., Allerton, Timothy D., Kapusta, Daniel R., Lefer, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Precision Medicine/Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129481/
http://dx.doi.org/10.1017/cts.2023.404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129481/
http://dx.doi.org/10.1017/cts.2023.404

Ejemplares similares